12 maart 2022: ASCO GU 2022

Alle abstracten gepresenteerd op het American Society of Clinical Oncology Genitourinary Cancers Symposium 2022 gerelateerd aan blaaskanker en 1 abstract specifiek gerelateerd aan urineleiderkanker

Voor blaaskanker zijn dat 168 abstracten en aan te klikken via deze PDF

Voor urineleiderkanker is het maar 1 abstract namelijk deze:

Primary urethral cancer:
A GETUG French nationwide cohort study. Ilfad Blazevic, Aude Flechon, Geraldine Pignot, Beno^ıt Mesnard, Jerome Rigaud, Mathieu Roumiguie, Michel Soulie, Constance Thibault, Laurence Crouzet, Camille Goislard De Monsabert, Felix Lefort, Marine Gross-Goupil, Lucas Campedel, Mathieu Laramas, Elodie Martin, Leonor Chaltiel, Damien Pouessel; Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Toulouse, France; Centre Leon B erard, Lyon, France; Institut Paoli-Calm- ettes, Marseille, France; Centre Hospitalier Universitaire de Nantes, Nantes, France; Centre Hospitalier Universitaire Toulouse Rangueil, Toulouse, France; Medical Oncology Department, Georges Pompidou Hospital, AP-HP. Centre-Universite de Paris, Paris, France; Centre Eug ene Marquis, Ren- nes, France; Hopital Saint-Andr ^ e, Bordeaux University Hospital, Bordeaux, France; Centre Hospitalier Universitaire de Bordeaux-Hopital Saint-Andr ^ e, Bordeaux, France; Groupe Hospitalier Piti e-Sal- petri ^ ere, Paris, France; Grenoble University Hospital, Grenoble, France

Background: Primary urethral cancer (PUC) is a rare and heterogeneous malignancy. Due to its scarcity, little data are available on the optimal treatment sequence and survival, especially in metastatic patients.

Methods: Data from patients diagnosed with a PUC between 01/01/2000 and 12/31/2018 were retrospectively collected from nine French referral centers. Survival rate were estimated with the Kaplan-Meier method and prognostic factors were analyzed using the Cox proportional hazards model and the log-rank test. In order to increase the statistical power of survival analysis in the metastatic stage, patients with synchronous and metachronous metastatic disease were pooled.

Results: We identified 44 (62%) males and 27 (38%) females with a PUC. The most frequent histological types were urothelial carcinomas (40.0%), squamous cell carcinomas (34.3%) and adenocarcinomas (14.3%). Twenty-five (35.2%) patients were diagnosed at a localized stage (≤ T2, N0, M0); 35 (49.3%) at a locally advanced stage (≥ T3 or ≥ N1, M0) and 11 (15.5%) at a distant stage (M1). Twenty-seven patients had a metachronous metastatic cancer. Multimodality therapy was used in 24.0% and 57.1% of the patients with a localized and locally advanced disease, respectively. In the entire cohort, median overall survival (OS) was 52.5 months (IC95% 32.2 – 64.1) and stage at diagnosis was a predictor of OS (p < 0.0001). For the 60 patients with a non-metastatic disease, 39 (65%) had a recurrence or were dead and the median disease-free survival (DFS) was 21.2 months (IC95% 16.8 – 34.5). Nodal involvement was the only factor associated with DFS (HR: 2.03, p = 0.0390).
Multimodal treatment compared with unimodal treatment was not significantly associated with DFS (HR: 1.22, p = 0.5419). Regarding survival of the 38 metastatic patients, the median OS was 15.2 months (IC95% 8.2 – 23.5) and the median progression-free survival was 6.4 months (IC95% 4.4 – 9.8).

Conclusions: This retrospective study showed an important heterogeneity in terms of histology, stage at diagnosis, and treatment of PUC. In this cohort, the multimodal approach did not show any improvement in survival of non-metastatic patients. This study is one of the few to describe the survival in metastatic patients. Research Sponsor: None.

Plaats een reactie ...

Reageer op "ASCO GU 2022: Abstracten gerelateeerd aan blaaskanker en urineleiderkanker gepresenteerd op het American Society of Clinical Oncology Genitourinary Cancers Symposium van 17 t/m 19 februari 2022"

Gerelateerde artikelen

Gerelateerde artikelen

ASCO GU 2022: Abstracten gerelateeerd >> ASCO 2020: aanbevolen abstracten >> ASCO 2022: aanbevolen abstracten >>